Brimonidine tartrate; timolol maleate - Generic Drug Details

What are the generic drug sources for brimonidine tartrate; timolol maleate and what is the scope of patent protection?

Brimonidine tartrate; timolol maleate is the generic ingredient in two branded drugs marketed by Alembic, Amneal, Apotex, Caplin, Glenmark Pharms Ltd, Regcon Holdings, Sandoz, Sentiss, Somerset, Upsher Smith Labs, and Abbvie, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

Thirteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for brimonidine tartrate; timolol maleate

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	11
Finished Product Suppliers / Packagers:	13
Clinical Trials:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for brimonidine tartrate; timolol maleate
DailyMed Link:	brimonidine tartrate; timolol maleate at DailyMed

Recent Clinical Trials for brimonidine tartrate; timolol maleate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of So Paulo	PHASE4
Allergan	Phase 3
Allergan

See all brimonidine tartrate; timolol maleate clinical trials

Generic filers with tentative approvals for BRIMONIDINE TARTRATE; TIMOLOL MALEATE

Applicant	Application No.	Strength	Dosage Form
		0.2%; 0.5%	SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for brimonidine tartrate; timolol maleate

Drug Class	alpha-Adrenergic Agonist beta-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for brimonidine tartrate; timolol maleate

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GA	Sympathomimetics used as decongestants
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for BRIMONIDINE TARTRATE; TIMOLOL MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMBIGAN	Ophthalmic Solution	brimonidine tartrate; timolol maleate	0.2%/0.5%	021398	1	2008-11-21

US Patents and Regulatory Information for brimonidine tartrate; timolol maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	091087-001	Apr 4, 2022	AB	RX	No	No
Caplin	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	219093-001	Feb 25, 2025	AB	RX	No	No
Apotex	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	091442-001	Apr 20, 2022	AB	RX	No	No
Alembic	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	215230-001	Aug 25, 2023	AB	RX	No	No

Expired US Patents for brimonidine tartrate; timolol maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007
Abbvie	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007
Abbvie	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007
Abbvie	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007

Market Dynamics and Financial Trajectory for Brimonidine Tartrate and Timolol Maleate

Last updated: February 19, 2026

Brimonidine tartrate and timolol maleate are established medications used in the treatment of glaucoma and ocular hypertension. Both drugs are available in multiple formulations, including fixed-dose combinations, and are marketed globally. The market for these drugs is influenced by factors such as patent status, generic competition, evolving treatment guidelines, and demographic shifts.

Market Overview

Parameter	Brimonidine Tartrate	Timolol Maleate
Therapeutic Class	Alpha-2 adrenergic agonist; eye drops	Non-selective beta-blocker; eye drops
Approved Uses	Open-angle glaucoma; ocular hypertension	Open-angle glaucoma; ocular hypertension
Birth Year	1996 (initial approval in the U.S.)	1978 (initial approval in the U.S.)
Number of Marketed Brands	3 major brands (Alphagan, Lumify, others)	Multiple generics; branded options
Patent Status	Patent expired; some formulations still patent-protected	Patent expired; many generics available

Revenue and Market Size

The global glaucoma medication market was valued at approximately USD 5 billion in 2022, with eye drops accounting for a majority of this figure. Brimonidine tartrate and timolol maleate occupy significant segments:

• Brimonidine: USD 300-500 million annually, driven by brand sales and generics.
• Timolol: USD 600-800 million annually, with higher market penetration.

The combined market share for fixed-dose combination products containing these drugs exceeds 20% of the eye drop segment.

Market Drivers

1. Generic Competition: Since patent expirations (timolol in 2003, brimonidine around 2016), the entry of generics has cut prices substantially, pressuring brand revenues.
2. Treatment Guidelines: Favor first-line use of beta-blockers like timolol; newer agents like brimonidine are positioned as adjuncts or alternatives.
3. Demographic Trends: Aging populations in the U.S., Europe, and Asia increase prevalence of glaucoma, raising demand.
4. Formulation Innovation: Development of fixed-dose combinations (e.g., brimonidine/timolol) enhances patient adherence and expands market size.
5. Regulatory Environment: Abbreviated pathway approvals for generics expedite market entry, intensifying competition.
6. Regional Variations: High-growth markets include India, Southeast Asia, and Latin America, where affordability and access expand user bases.

Financial Trajectory Analysis

Year	Estimated Revenue (USD Million)	Trend	Key Factors
2022	900	Steady but declining due to generic pressure	Patent cliffs, price erosion
2025	850	Slight decline expected	Increased generic penetration, price cuts
2030	700	Further decline unless market expansion occurs	Patent expiration, new formulations

Forecasts indicate a 1-3% annual decline without significant market expansion, but region-specific growth could offset declines in mature markets.

Competitive Landscape

• Major Brands: Allergan (now part of AbbVie), Santen, and Alcon market brimonidine and timolol products.
• Generics: Multiple manufacturers produce t Timolol and brimonidine generics with pricing 50-70% lower than branded products.
• Innovators: Limited pipeline activity; focus remains on combination therapies and delivery systems rather than monotherapy breakthroughs.

Key Market Challenges and Opportunities

Challenges	Opportunities
Price erosion due to generics	Development of sustained-release formulations
Stagnant innovation in monotherapy	Expansion into emerging markets
Side effect profiles limiting use	Personalized medicine approaches

Policy and Regulatory Impact

• Patent Laws: Variations in patent enforcement affect market stability.
• Pricing Regulations: Price controls in countries like Canada, the UK, and Australia impact revenues.
• Reimbursement Policies: Coverage decisions influence prescribing patterns; generics favored if heavily subsidized.

Conclusions

Brimonidine tartrate and timolol maleate face a matured market with declining revenues driven by generic competition and patent expirations. Strategic growth may depend on regional expansion, fixed-dose combination development, and pipeline innovation. Long-term financial prospects largely hinge on navigating market commoditization and leveraging regional growth opportunities.

---

Key Takeaways

• The market for brimonidine tartrate and timolol maleate is mature, with revenues declining globally.
• Generics dominate market share, with prices decreasing significantly since patent expirations.
• Fixed-dose combinations and regional expansion present growth opportunities amid typical patent expiry impacts.
• Regulatory, policy, and reimbursement environments influence revenue trajectories.
• Innovation is limited, emphasizing the importance of formulary positioning and market access strategies.

---

FAQs

1. When did the patents for brimonidine tartrate and timolol maleate expire?
Brimonidine tartrate's primary patent expired around 2016, while timolol's patent expired in 2003 [1].

2. What are the main barriers to market growth for these drugs?
Gaining access to emerging markets, price competition from generics, and limited pipeline innovation restrict growth.

3. How do fixed-dose combinations affect the market?
They improve patient adherence, justify higher pricing compared to monotherapies, and are driving some revenue expansion.

4. Which regions are experiencing the fastest growth for these medications?
India, Southeast Asia, and Latin America show the fastest growth due to increasing disease prevalence and improved access.

5. What is the outlook for branded versus generic sales?
Branded sales decline while generic sales continue to dominate revenue streams, although market share shifts toward generics annually.

---

References

1. U.S. Food and Drug Administration. (2021). Patents and exclusivity. Retrieved from [FDA website]